Reuters logo
BRIEF-Biocryst announces Rapivab pediatric SNDA acceptance
June 5, 2017 / 10:36 AM / 6 months ago

BRIEF-Biocryst announces Rapivab pediatric SNDA acceptance

June 5 (Reuters) - BioCryst Pharmaceuticals Inc-

* BioCryst announces rapivab® pediatric snda acceptance

* Says snda has been classified by fda as a priority review

* Says snda has a pdufa goal date for a decision by end of september 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below